Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma

Fig. 6

Negative correlation between IRF6 promoter methylation and expression in TCGA bladder cancer dataset. a DNA methylation level (β-value from Illumina Infinium 450 K methylation microarray) of IRF6 promoter CpG island from − 259 (cg23283495) to + 408 (cg1603017) in high (red) vs low (green) stage tumor in TCGA bladder cancer dataset. Although most of the probes showed low methylation level in general, high-staged tumor has higher methylation level than low-staged tumor. X-axis indicates the name of the probe on the microarray. b The β-value of each patient in low- (upper panel, green) or high- (lower panel, red) staged group was transformed into color scale for the heatmap. The definition of the color scale is also shown in the color bar below. c A lower expression of IRF6 is observed in patients with high stage tumor, as compared with low stage in TCGA bladder cancer dataset (n = 382, P = 0.184). d Scatter plot showing correlation between IRF6 promoter methylation (cg16030177, x-axis) and expression (y-axis) in the TCGA bladder cancer dataset. A negative correlation between promoter methylation and expression was observed

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us